CSRxP Commends Congressional Probe Of Big Pharma Giant’s Anti-Competitive Tactics and Egregious Pricing Practices

U.S. House Oversight Committee Subpoena of AbbVie Related to Pricing of Blockbuster Cancer, Immunosuppressant Drugs Will Help Hold Industry Accountable

For Immediate Release
Contact: Jon Conradi
[email protected]

Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement Tuesday in response to news that the U.S. House Oversight Committee will subpoena Big Pharma giant AbbVie to obtain documents related to the company’s pricing of blockbuster cancer drug Imbruvica and immunosuppressive drug Humira.

“AbbVie has a long track record of gaming the system to block competition and keep prices high in order to boost profits,” said CSRxP executive director Lauren Aronson. “We commend lawmakers’ commitment to getting the facts on AbbVie’s shady tactics and egregious pricing practices in order to help hold Big Pharma accountable.”

“Just this year, AbbVie has hiked the price of its products 50 times, including increasing the price of Humira yet again, despite the drug’s price almost doubling in recent years,” Aronson continued. “As millions of Americans struggle to afford their prescription drugs, Congress must advance bipartisan, market-based solutions to hold drug companies like AbbVie accountable.”

AbbVie is among the most notorious Big Pharma companies that game the system to undermine competition and keep prices high – particularly around its blockbuster cancer drug Imbruvica and arthritis drug Humira.

Imbruvica and Humira Demonstrate How AbbVie Abuses The Patent System To Increase Profits And Keep Drug Prices High For Millions Of American Patients.

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.